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Abstract
Background: The goal of this study was to determine the effects of a selective Cyclooxygenase
(COX)-2 inhibitor on the inhibition of tumor growth and pulmonary metastasis in a Lewis Lung
Carcinoma (LLC) animal model.
Methods: For immunoblot analysis of COX-2 and PGE2, cells were treated with irradiation in the
presence or absence of celecoxib. The right thighs of male, 6-week old C57/BL mice were
subcutaneously injected with 1 × 106 LLC cells. The animals were randomized into one of six
groups: (1) no treatment, (2) 25 mg/kg celecoxib daily, (3) 75 mg/kg celecoxib daily, (4) 10 Gy
irradiation, (5) 10 Gy irradiation plus 25 mg/kg celecoxib daily, and (6) 10 Gy irradiation plus 75
mg/kg celecoxib daily. Mice were irradiated only once, and celecoxib was administered orally. Mice
were irradiated with 4-MV photons once the tumor volume of the control group reached 500 mm3.
All mice were sacrificed when the mean tumor volume of control animals grew to 4000 mm3. The
left lobes of the lungs were extracted for the measurement of metastatic nodules.
Results: Irradiation resulted in a dose-dependent increase in PGE2 production. PGE2 synthesis
decreased markedly after treatment with celecoxib alone or in combination with irradiation.
Compared to mice treated with low dose celecoxib, mean tumor volume decreased significantly in
mice treated with a high dose of celecoxib with or without irradiation. Mice treated with a high
dose celecoxib alone, with irradiation alone, or with irradiation plus celecoxib had markedly fewer
metastatic lung nodules than controls. The mean metastatic area was the smallest for mice treated
with irradiation plus a high dose celecoxib.
Conclusion: Oral administration of high dose celecoxib significantly inhibited tumor growth, as
compared to a low dose treatment. Radiotherapy in combination with high dose celecoxib delayed
tumor growth and reduced the number of pulmonary metastases to a greater extent than celecoxib
or radiotherapy alone.
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Background
Radiotherapy is a common treatment for localized can-
cers. The radiation dose is important for tumor control.
However, the therapeutic efficacy of radiotherapy is often
limited by normal tissue damage within or nearby the
field of radiation. In clinical practice, the radiation dose is
optimized according to the probability of tumor control
compared to the risks of complications due to the effects
on normal tissue [1,2]. Combining chemotherapeutic
agents concurrently with radiotherapy has improved
tumor control and survival. However, this combined
approach also increases systemic and local toxicities dur-
ing radiotherapy. Because of the increased toxicity, the
overall treatment duration of radiotherapy, in addition to
chemotherapy, is usually prolonged when compared to
the treatment time of radiotherapy alone [3,4]. This
increased duration may decrease its efficacy for tumor
control within the radiation field.
To further improve tumor response and reduce normal
tissue toxicity from radiotherapy or chemoradiotherapy,
many novel approaches have investigated several agents
in preclinical and clinical settings. These approaches
include those that selectively interfere with certain molec-
ular processes and signaling pathways that regulate prolif-
eration, survival, and function of normal cells. Because
these agents are preferentially associated with specific sites
of the cancer cells, their targeting is predicted to improve
the tumor response to radiotherapy or chemoradiother-
apy without additional toxicity to normal tissue. Among
these agents, inhibition of cyclooxygenase (COX)-2 has
been investigated as a potentially useful agent for the
treatment of cancer.
COX-2 is normally present in cells and tissues of the brain
and kidneys, but is induced in pathological states such as
inflammation and tumors. COX-2 promotes carcinogene-
sis, tumor proliferation, angiogenesis, prevention of
apoptosis, and immunosuppression [5]. COX-2 overex-
pression has been associated with tumor behavior and
prognosis in several cancers [6]. Selective inhibition of
COX-2 activity in several animal models has been associ-
ated with the decrease of new blood vessel production in
tumors, a decrease in new vessel formation and an
increase in tumor cell apoptosis. The selective inhibition
of COX-2 activity has been associated with enhanced radi-
ation sensitivity of tumors without enhancing the effects
of radiation on normal tissue [7-9].
In this study, we evaluated the effect of a selective COX-2
inhibitor as a radiation sensitizer in order to inhibit tumor
growth and pulmonary metastasis in a Lewis Lung Carci-
noma (LLC) animal model.
Methods
Animals and Tumor Cells
Male, 6-week old C57/BL mice (Ajou animal laboratory,
Suwon, Korea) were used for these experiments. The mice
were acclimated for 1 week, and caged in groups of five or
less in an air conditioned room. Mice were fed a diet of
animal chow and water ad libitum. LLC cells were pur-
chased from the American Type Tissue Collection. LCC
cells were maintained in DMEM supplemented with 10%
fetal bovine serum and penicillin-streptomycin. Cells
were grown in monolayers in 100 mm dishes, and were
maintained in a humidified 5% CO2 incubator at 37°C.
Celecoxib
Stock solutions of celecoxib were made by dissolving the
compound in DMSO, then were stored at -20°C. Concen-
trated drug stocks were diluted in DMEM before adminis-
tration to cells or mice.
Immunoblot Analysis of COX-2
Cells were pretreated with 10 or 30 μM celecoxib for 1 h
at 37°C. After treatment, the cells were irradiated at a dose
of 5 Gy or 10 Gy. At 24 or 48 h post treatment, the cells
were washed twice with PBS and lysed in buffer (Upstate).
Supernatant protein concentrations were determined by
Bradford assay using bovine serum albumin (BSA, Sigma
Chemical Co.) as a standard. Aliquots of total protein (40
μg) was denatured and fractionated by SDS-polyacryla-
mide gel electrophoresis (4–12% gels). The separated pro-
teins were transferred to a 0.22 μm nitrocellulose
membrane. The nonspecific binding sites were blocked
for 1 h in 5% non-fat dry milk and in Tris-buffered saline
(TBS). The membranes were incubated with monoclonal
anti-COX-2 (610204, BD biosciences) and anti-α tubulin
(Oncogene) for approximately 1 h at room temperature.
The membranes were washed in buffer containing TBS
plus 0.05% Tween-20 and incubated in the appropriate
secondary antibody (P0447, Dakocytonation). Signals
were detected using enhanced chemiluminescence
(Pierce).
Determination of PGE2 Synthesis
1 × 106 cells were either untreated, or treated with 30 μM
celecoxib for 1 hr and then with 0, 5, or 10 Gy irradiation.
After each treatment, supernatant PGE2 levels were
assayed in triplicate. Determination of PGE2 levels by
enzyme immunoassay was accomplished using a PGE2
monoclonal enzyme immunoassay kit (Cayman Chemi-
cal). Quantification was performed according to the man-
ufacturer's instructions.
In vivo Tumor Growth and Quantitation of Lung 
Metastases
A suspension of 1 × 106 LLC cells in 0.1 ml of growth
medium was injected subcutaneously into the shavedJournal of Experimental & Clinical Cancer Research 2008, 27:66 http://www.jeccr.com/content/27/1/66
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right thighs of mice. The study groups (n = 12 per group)
consisted of an untreated control (group 1), 25 mg/kg
celecoxib daily (group 2), 75 mg/kg celecoxib daily
(group 3), 10 Gy irradiation (group 3), 10 Gy irradiation
plus 25 mg/kg celecoxib daily (group 5), and 75 mg/kg 10
Gy irradiation plus celecoxib daily (group 6).
Celecoxib was administered by lavage (0.1 mL) every
afternoon from one day before the cell injection until the
day of euthanasia or death. For tumor irradiation, mice
were put under general anesthesia and restrained using
adhesive tape and customized devices constructed from a
50 ml syringe. Once the tumors in the control group
reached a mean volume of 500 mm3, the tumors in the
right thighs were irradiated with 10 Gy using a 4 MV x-ray
for one fraction. Following injection of the tumor cells,
the primary tumors were measured three times a week at
two perpendicular diameters using a Vernier caliper, and
tumor volumes were evaluated based on the formula, vol-
ume = 0.5 × a × b2 where a = length and b = width.
All mice were euthanized when the mean tumor volume
in the control group reached 4000 mm3. The left lobes of
the lungs were extracted, fixed in 10% formalin, and proc-
essed for the quantitation of metastatic nodules. The
number of metastatic nodules was measured in the maxi-
mum sagittal plane from 5 μm paraffin-embedded lung
tissue sections. The dimension of the outlined metastatic
nodule was automatically calculated using commercial
software (i solution DT, Seoul, Korea).
Statistical Analysis
The primary tumor volumes were expressed as the mean
and standard deviation. Comparison of the area of the
lung nodules and tumor volumes among the experimen-
tal groups was determined by the Wilcoxon rank-sum test.
The correlation between tumor volume and area of the
metastatic lung nodules was evaluated by regression anal-
ysis. P-values less than 0.05 were considered statistically
significant. All statistical analyses were performed with
the SAS® System (SAS 14.0, SAS Institute Inc., Cary, NC.,
USA).
Results
In vitro, Effect of the Selective COX-2 Inhibitor on LLC 
Cells
LLC cell COX-2 protein expression was confirmed by
western blot analysis, which showed constitutive COX-2
expression (Figure 1). Differences in the amount of COX-
2 protein expression were not observed after irradiation
alone. However, COX-2 expression increased with
celecoxib treatment alone and with irradiation plus
celecoxib. Irradiation was associated with a dose-depend-
ent increase in PGE2 production, as measured by enzyme
immunoassay (Figure 2). PGE2 synthesis decreased mark-
edly after treatment with celecoxib alone or with celecoxib
in combination with irradiation. Radiation treatment plus
celecoxib did not increase PGE2 production when com-
pared to celecoxib alone, regardless of the radiation dose.
In vivo Tumor Growth
When the mean volume of the tumors in the control
group reached 539.6 mm3 (487~589 mm3), 11 days after
LLC cell injection, the animals in irradiation alone or celo-
coxib plus irraditation were irradiated. At 20 days after
injections, a protruding tumor and areas of denuded sur-
face were found at the injection sites, especially in control
mice. The mean tumor volume in the control group
increased to 3802.2 mm3 (3466~4332 mm3), and all mice
were euthanized as planned. At that time, the mean tumor
volumes of groups 2, 3, 4, 5, and 6 were 3814.4 mm3
(2225~5421 mm3), 2757.6 mm3  (1995~3395 mm3),
1942.1 mm3  (1766~2275 mm3), 1874.3 mm3
(1341~2437 mm3), and 1319.3 mm3 (989~1815 mm3),
respectively (Figure 3).
Compared to the control group, the mean tumor volume
decreased significantly in all treatment groups, except for
those treated with 25 mg/kg celecoxib daily (Table 1). The
effect of celecoxib on the delay of tumor growth was dose-
dependent. Compared to the mice treated daily with 25
mg/kg celecoxib, the mean tumor volumes decreased sig-
nificantly in the mice treated daily with 75 mg/kg
celecoxib, with or without irradiation (p = 0.0135, p =
0.0144). The delay in tumor growth was evident in the
irradiated groups, regardless of the celecoxib dose.
In vivo Lung Metastasis
The prevalence of detected lung metastases from groups 1
to 6 were 100%, 100%, 75.0%, 50.0%, 87.5%, and 25%,
respectively. The mean area of the metastatic lung nodules
did not differ between mice treated with low dose
celecoxib (25 mg/kg) only and the control group (Table
2). However, the area of metastatic lung nodules
decreased significantly in mice treated with high dose
celecoxib (75 mg/kg) alone or with irradiation with or
without celecoxib. Among the mice treated with irradia-
tion, the mean metastatic area was smaller than in the
control group. The mean metastatic area was the smallest
in mice treated with irradiation and 75 mg/kg celecoxib
daily (group 6); however, the difference was only margin-
ally significant (p = 0.0675). The area of metastatic lung
nodules significantly correlated with tumor volume,
regardless of treatment (Figure 4).
Discussion
COX-2 expression has been reported in a variety of
human cancers such as breast, lung, colon, cervix, liver,
and prostate. Among tumors types, the intensity or distri-
bution of COX-2 varies. However, COX-2 overexpressionJournal of Experimental & Clinical Cancer Research 2008, 27:66 http://www.jeccr.com/content/27/1/66
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has been associated with tumor differentiation, tumor
size, stage, and metastasis. In several cancers, patients with
COX-2 overexpression have a poor prognosis [10-14].
Denkert et al. immunohistochemically evaluated COX-2
expression from breast cancer specimens. They reported
more lymph node metastasis, larger tumors, poor differ-
entiation, increased vascular invasion, and negative estro-
gen receptor status in patients with elevated COX-2
expression. COX-2 overexpression was reported to be of
borderline significance for disease-free survival (relative
risk 1.90). Sheehan et al. showed that high COX-2 expres-
sion correlates with advanced stage disease and larger
tumors in patients with colorectal cancer.
COX-2 associates with tumor growth, infiltration, and
metastasis in preclinical experiments. Tsujii et al. studied
the phenotypic and biochemical changes associated with
COX-2 expression. Rat intestinal epithelial cells were
infected with a COX-2 expression vector oriented in the
sense (RIE-S) or anti-sense (RIE-AS) direction. RIE-S cells
demonstrated increased adhesion to extracellular matrix
proteins and inhibition of apoptosis, compared with RIE-
AS cells. After human colon cancer cells (Caco-2) were
transfected with a COX-2 expression vector, Caco-2 cells
acquired increased invasiveness compared with parental
cells [15,16]. Liu et al. showed that transgenic mice over-
expressing COX-2 in the mammary gland, expressed
COX-2 during pregnancy and lactation. Multiparous
transgenic mice, but not virgin mice, exhibited a high inci-
dence of focal mammary gland hyperplasia, dysplasia,
and transformation into metastatic tumors [17].
Nonsteroidal anti-inflammatory drugs (NSAID) are
widely used for relief of inflammatory pain worldwide.
Several population-based reports have demonstrated a
40% decrease in the death rate in persons with digestive
tract cancers who regularly used aspirin, compared to
those who did not. Clinical trials with NSAID in patients
with Familial Adenomatous Polyposis clearly demon-
strated that NSAID treatment shrunk pre-existing adeno-
mas [18-20]. In addition, indomethacin offered palliative
support to patients with advanced solid tumors, and pro-
longed their mean survival compared to placebo-treated
patients [21]. The mechanism of NSAID action was
unknown until in 1971, when Vane proposed that
NSAIDs primarily suppress inflammation by inhibiting
COX and by limiting the production of PG [22]. NSAIDs
non-selectively inhibit the activities of both COX-1 and
COX-2. COX-1 inhibition causes the adverse effects of
NSAIDs on the gastrointestinal tract [23,24]. In a rand-
Celecoxib effects on COX-2 protein expression Figure 1
Celecoxib effects on COX-2 protein expression. Western blot analysis showed constitutive expression of COX-2 pro-
tein in vehicle treatment as a control.Journal of Experimental & Clinical Cancer Research 2008, 27:66 http://www.jeccr.com/content/27/1/66
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omized, placebo-controlled endoscopic evaluation, Sche-
iman et al. reported that the short-term use of
nonselective COX inhibitors associated with a signifi-
cantly greater ulceration rate, compared with a placebo
[25].
The development of selective COX-2 inhibitors, with
decreased potential for gastrointestinal toxicity, has stim-
ulated additional investigations. Numerous studies on the
antineoplastic effects of selective COX-2 inhibitors have
been performed. Williams et al. proposed that celecoxib
reduced the viability of cell lines, including LLC cells,
from the induction of apoptosis and the growth of tumors
in vivo, and had no effect on apoptosis or the epithelium
of the normal gut [26]. Leahy et al. reported that a reduc-
tion in proliferation and an increase in apoptosis were
observed in colorectal tumor cells in response to celecoxib
[27]. Connolly et al. proposed that in vitro COX inhibitors
decreased vascular endothelial growth factor production
and increased apoptosis of tumor cells, as well as a
reduced primary tumor weight, the number of lung
metastases, and microvessel density in primary tumors in
mice [28]. Kobayashi et al. showed that selective COX-2
inhibition in colon cancer cell lines reduced the diameter
of the tumor vessels as well as the number and size of the
metastatic nodules in the lung. In addition, dose-depend-
ent selective COX-2 inhibition reduced the size of meta-
static tumors [9].
In our study, we used western blot analysis to confirm that
a COX-2 inhibition increased COX-2 expression. The
effect of celecoxib on the delay of tumor growth was dose-
dependent, regardless of irradiation. High dose celecoxib
(75 mg/kg celecoxib daily) significantly reduced the
tumor volume, compared to control and low dose
celecoxib groups. The rate of lung metastasis was
decreased by about 25% in the high dose celecoxib group,
compared to the control group. In addition, the area of
metastatic lung nodules decreased significantly in the
high dose celecoxib group.
With irradiation, COX-2 expression increased in tumors
and associated with increased PGE2 levels. Steinauer et al.
observed a dose-dependent increase in COX-2, following
irradiation. PGE2 levels in irradiated cells were higher
than in controls, and decreased when combined with a
COX-2 inhibitor [29]. The mechanisms underlying the
radiation-enhancing effects of COX-2 inhibitors include
(1) an accumulation of cells in the G2/M phases of the cell
cycle which are considered to be sensitive to irradiation;
(2) a reduction of PG-induced immunosuppressive activ-
ity caused by antitumor immunologic responses capable
of potentiating tumor responses to radiation; and (3)
Celecoxib effects on PGE2 production Figure 2
Celecoxib effects on PGE2 production. PGE2 production (normalized to 106 cells) by ELISA in Lewis Lung Carcinoma 
cells after irradiation with single doses of 5 and 10 Gy alone and in combination with 30 μM.Journal of Experimental & Clinical Cancer Research 2008, 27:66 http://www.jeccr.com/content/27/1/66
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direct effects on tumor neovascularization [7,30,31]. Shin
et al. reported that celecoxib's radiation-enhancing effect
was observed in COX-2 expressing cells but was not
observed in COX-2 non-expressing cells. The radiation-
enhancing effects disappeared in cells treated with COX-
2-specific siRNA [32]. LLC cells express COX-2 [26]. In
this study, we confirmed COX-2 expression by western
blotting. Unlike Steinauer et al., irradiation, regardless of
Table 1: Wilcoxon rank-sum test for mean tumor volume at 20 days after tumor cell injection in control and treatment groups (p-
value).
Groups Control Celecoxib 25 mg/kg Celecoxib 75 mg/kg RT RT + Celecoxib 25 mg/
kg
RT + Celecoxib 75 mg/
kg
Control - 0.9761 0.0004 < 0.0001 < 0.0001 < 0.0001
Celecoxib 25 mg/kg 0.9761 - 0.0135 < 0.0001 0.0002 < 0.0001
Celecoxib 75 mg/kg 0.0004 0.0135 - 0.0004 0.0023 < 0.0001
RT < 0.0001 < 0.0001 0.0004 - 0.7238 0.0001
RT + Celecoxib 25 mg/
kg
< 0.0001 0.0002 0.0023 0.7238 - 0.0144
RT + Celecoxib 75 mg/
kg
< 0.0001 < 0.0001 < 0.0001 0.0001 0.0144 -
RT: radiation
Celecoxib effects the in vivo tumor growth of Lewis lung carcinoma cells. Figure 3
Celecoxib effects the in vivo tumor growth of Lewis lung carcinoma cells. Dose dependent delay of tumor growth 
with celecoxib in mice regardless of irradiation.Journal of Experimental & Clinical Cancer Research 2008, 27:66 http://www.jeccr.com/content/27/1/66
Page 7 of 9
(page number not for citation purposes)
the dosage, did not increase COX-2 expression. However,
PGE2 levels increased with irradiation in a dose-depend-
ent manner. Tumor growth was delayed as a result of irra-
diation, especially in mice treated by irradiation and high
dose celecoxib, where tumor growth was markedly
delayed. The area of metastatic lung nodules was signifi-
cantly smaller in mice treated by irradiation, regardless of
celecoxib dose, than in the control group. Lung metastases
were detected in only 25% of the mice treated by irradia-
tion plus high dose celecoxib, as compared to 100% of the
control mice.
The surgical removal of a primary tumor or radiation in
order to eradicate a primary tumor can result in rapid
growth and metastasis [33,34]. Camphausen et al.
reported that a single or hypofractionated irradiation pro-
tocol for the eradication of primary LLC cells increased the
number of surface lung metastases in irradiated animals,
as compared to controls. However, in our study, the
number of lung metastases decreased from 100% in con-
trol mice to 50% in mice treated with irradiation alone.
The differences between these two studies may be due to
the doses used, i.e., whether it was a curative dose or not.
We did not irradiate the primary tumor for eradication
because we were studying the effects of a selective COX-2
inhibitor as a radiation sensitizer for the inhibition of
tumor growth and pulmonary metastasis.
In conclusion, a high dose oral treatment of celecoxib sig-
nificantly inhibited tumor growth, compared to a low
dose treatment. In mice treated with radiotherapy and a
high dose celecoxib, delay of tumor growth and reduction
of pulmonary metastases were more prominent than in
the mice treated with celecoxib or radiotherapy alone.
Regression analysis showed a significant correlation between the area of metastatic lung nodules and tumor volume regardless  of treatment. Figure 4
Regression analysis showed a significant correlation between the area of metastatic lung nodules and tumor 
volume regardless of treatment.Journal of Experimental & Clinical Cancer Research 2008, 27:66 http://www.jeccr.com/content/27/1/66
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However, further studies are needed to evaluate the effect
of selective COX-2 inhibitors combined with conven-
tional fractionation or hypofractionation radiotherapy on
various cancer cell lines with regard to the delay of tumor
growth and inhibition of metastasis.
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